The company uses bryostatin technology to activate and sensitize cells, amplifying immune response and clearance by immunotherapeutic agents and innate host immune mechanisms. BryoLogyx has exclusive rights to use this method in cancer and other diseases, and is preparing to start clinical studies in collaboration with the NCI. Bryostatin has been clinically tested in over 1100 patients, with an established safety profile.